A CRA expert was retained in an antitrust class action matter on behalf of a branded pharmaceutical manufacturer in which plaintiffs alleged inappropriate listings of patents in the FDA’s Orange Book under the Hatch-Waxman Act, sham patent litigation, and attempted monopolization. CRA’s expert economic analyses demonstrated the branded pharmaceutical competed broadly with other products and that plaintiffs’ but-for model lacked validity.
Lexology Index recognizes 44 CRA competition experts globally
This year, 44 CRA experts were named among the leading Competition Economists, with four recognized as Competition Future Leaders – Economists. This...